Safety and Efficacy of Disitamab Vedotin Combined With Sintilimab as First-line Treatment of Elderly Patients With HER2 Overexpression Gastric Cancer
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 20
- 主要终点
- PFS (Progression-Free-Survival)
研究概览
简要总结
This study aims to explore the safety and efficacy of Disitamab vedotin combined with Sintilimab in elderly patients with HER2 overexpression Gastric Cancer. This is a single-arm exploratory clinical study. 20 patients with eHER2 overexpression gastric cancer are scheduled to be enrolled. Treatment regimen is Disitamab vedotin 2.5mg/kg and Sintilimab 200mg every 21 days, until disease progression or intolerable adverse reactions or death.
详细描述
The primary objective of this study was to explore the safety and median PFS of Disitamab vedotin combined with Sintilimab as first-line treatment in elderly patients with HER2 overexpression Gastric Cancer.The secondary objective of this study was to evaluate the ORR, DCR, DOR and OS of Disitamab vedotin combined with Sintilimab as first-line treatment in elderly patients with HER2 overexpression Gastric Cancer.To provide a better treatment plan for elderly patients with Gastric Cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 65 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Volunteer to take part in the study ;
- •Age ≥65 , male or female;
- •Gastric cancer or adenocarcinoma of gastroesophageal junction confirmed by histology and/or cytology;
- •Have not received systematic treatment; If the subject has received adjuvant therapy after completing radical treatment for early gastric cancer and the subject has relapsed disease, ensure that the end of adjuvant therapy is more than 6 months from the first dose of the study and that various toxicities due to the adjuvant therapy have recovered.
- •The HER2 immunohistochemistry (IHC) test result is IHC 3+or 2+, and the previous test results of the subject (confirmed by the investigator) are acceptable;
- •At least one assessable lesion (RECIST 1.1 );
- •Expected survival time ≥ 6 months;
- •ECOG 0-2;
- •If the main organs function normally, they meet the following standards:
- •Blood routine examination (no blood transfusion and G-CSF use within 14 days before screening):
- •Hemoglobin ≥ 90 g/L;
- •Absolute neutrophil count (ANC) ≥ 1.5 × 109/L；
- •White blood cell count ≥ 3.0 × 109/L；
- •Platelet count ≥ 80 × 109/L；
- •Blood biochemical examination (albumin was not used within 14 days before screening):
- •Albumin ≥ 28 g/L;
- •Total bilirubin ≤ 2 × Upper limit of normal value (ULN);
- •In the absence of liver metastasis, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) ≤ 2.5 × ULN； ALT, AST and ALP ≤ 5× ULN in case of liver metastasis ；
- •Alkaline phosphatase (ALP) ≤ 5 × ULN；
- •Creatinine ≤ 1.5 × ULN； Or the creatinine clearance rate (CrCl) calculated by Cockcroft Gault formula is ≥ 50 mL/min;
- •Coagulation function:
- •International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN；
- •j) Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN。
排除标准
- •Have a history of malignant tumors other than gastric cancer, except for the following two cases:
- •The patient has received possible curative treatment and there is no evidence of the disease within 5 years;
- •The resected skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, cervical carcinoma in situ and other carcinoma in situ were successfully received;
- •Have received allogeneic stem cells or solid organ transplantation in the past;
- •Patients who have received other anti-tumor systemic therapy in the past (including traditional Chinese medicine with anti-tumor indications), and have been less than 4 weeks from the completion of treatment to the administration of this study, or the adverse events caused by previous treatment have not recovered to ≤ CTCAE level 1 (except hair loss and pigmentation);
- •Previous or current congenital or acquired immunodeficiency disease;
- •Allergic to the study drug;
- •Other significant clinical and laboratory abnormalities, which the researchers think affect the safety evaluation;
- •Serious infection in active period or poorly controlled clinically;
- •Not recovered from the operation;
- •Pregnant or lactating women, and women or men with fertility who are unwilling or unable to take effective contraceptive measures;
- •Other situations that the investigator thinks are not suitable for inclusion.
研究组 & 干预措施
Disitamab Vedotin Combined With Sintilimab
Treatment regimen is Disitamab vedotin 2.5mg/kg and Sintilimab 200mg every 21 days, until disease progression or intolerable adverse reactions or death.
干预措施: Disitamab Vedotin Combined With Sintilimab (Drug)
结局指标
主要结局
PFS (Progression-Free-Survival)
时间窗: 24 months
The time from randomization to tumor progression or death.The efficacy of this study was determined according to Recist version 1.1 criteria.
次要结局
- DOR（Duration of response）(24 months)
- OS (Overall survival time)(24 months)
- DCR（Disease control rate）(24 months)
- ORR（Objective Response Rate）(24 months)
- The Adverse Events(24 months)